GT Biopharma's GTB-3650 Advances Immunotherapy for Blood Cancer Treatment

GT Biopharma Advances Immunotherapy in Blood Cancer Treatment

GT Biopharma, Inc. is at the forefront of cancer treatment innovation, particularly with its promising immunotherapy drug, GTB-3650. The company recently completes a safety review for the third dosing group (Cohort 3) in its Phase 1 clinical trial, which focuses on patients with relapsed or refractory blood cancers, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The review reveals no safety or tolerability issues, allowing the company to progress to Cohort 4. In this next phase, patients will receive a dose of 10μg/kg/day, with screening currently underway and dosing expected to commence shortly.

GTB-3650 operates by enhancing the body’s natural killer (NK) cells, which play a crucial role in identifying and destroying cancerous cells. The treatment involves continuous infusions over a two-week period, followed by a two-week rest, and can be repeated for up to four months, contingent upon patient response. So far, six patients have been treated across initial cohorts, all of whom exhibit tolerability at increasing doses. The company notes promising trends in immunological biomarkers observed in these patients, suggesting that the upcoming Cohort 4 dosing may reflect a clinical efficacy threshold that could lead to substantial advancements in treatment options for these challenging cancer types.

As GT Biopharma pushes forward, the recent FDA approval of the first once-daily menin inhibitor for treating relapsed NPM1-mutated AML underscores the increasing recognition and demand for targeted therapies in blood cancer treatment. This growing market highlights the significance of GTB-3650, as it aims to address critical unmet needs for patients who have either not responded to or experienced a recurrence following initial therapies. The company plans to provide a comprehensive update in the first quarter of 2026, showcasing its commitment to developing advanced immunotherapy treatments that could transform the landscape of cancer care.

In summary, GT Biopharma's advancement of GTB-3650 represents a significant step forward in the battle against blood cancers. With its innovative approach to enhancing natural killer cell activity and the successful transition through clinical trial phases, the company is positioning itself as a leader in immunotherapy. As the landscape for blood cancer therapies evolves, GT Biopharma's efforts could play a pivotal role in improving outcomes for patients facing these formidable diseases.